(-)-Epicatechin regulates blood lipids and attenuates hepatic steatosis in rats fed high-fat diet

Molecular Nutrition and Food Research

Volumn 61, Issue 11, 2017, Pages

  Cheng, Hui ^a   Xu, Na ^b   Zhao, Wenxia ^c   Su, Jingjing ^a   Liang, Mengru ^a   Xie, Zhongwen ^b   Wu, Xianli ^d   Li, Qinglin ^a  

^a ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

^b ANHUI AGRICULTURAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^d BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

Blood lipids; Epicatechin; Hepatic steatosis; Hyperlipidemia; Insig 1 SREBP SCAP

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; CATECHIN; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; BLOOD; CHEMISTRY; CHOLESTEROL INTAKE; COMPARATIVE STUDY; DIETARY SUPPLEMENT; GENE EXPRESSION REGULATION; HYPERLIPIDEMIA; IMMUNOLOGY; LIPID DIET; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIOMARKERS; CATECHIN; CHOLESTEROL, DIETARY; CYTOKINES; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 85032688202     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201700303     Document Type: Article

References (54)

1. Le, N. A., Hyperlipidemia and cardiovascular disease. Curr. Opin. Lipidol. 2006, 17, 702–704.
2. Navar-Boggan, A. M., Peterson, E. D., D'Agostino, R. B., Sr., Neely, B. et al., Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015, 131, 451–458.
3. Nelson, R. H., Hyperlipidemia as a risk factor for cardiovascular disease. Prim. Care 2013, 40, 195–211.
4. Stone, N. J., Hyperlipidemia and cardiovascular disease. Curr. Opin. Lipidol. 1998, 9, 279–281.
5. Tveden-Nyborg, P., Birck, M. M., Ipsen, D. H., Thiessen, T. et al., Diet-induced dyslipidemia leads to nonalcoholic fatty liver disease and oxidative stress in guinea pigs. Translat. Res. 2016, 168, 146–160.
6. Last, A. R., Ference, J. D., Do, J. F., Pharmacologic treatment of hyperlipidemia. Am. Fam. Physician. 2011, 84, 551–558.
7. Hasani-Ranjbar, S., Nayebi, N., Moradi, L., Mehri, A. et al., The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr. Pharm. Des. 2010, 16, 2935–2947.
8. Chen, G., Wang, H., Zhang, X., Yang, S. T., Nutraceuticals and functional foods in the management of hyperlipidemia. Crit. Rev. Food. Sci. Nutr. 2014, 54, 1180–1201.
9. Ellam, S., Williamson, G., Cocoa and human health. Annu. Rev. Nutr. 2013, 33, 105–128.
10. Higginbotham, E., Taub, P. R., Cardiovascular benefits of dark chocolate? Curr Treat Options Cardiovasc Med 2015, 17, 54.
11. Kerimi, A., Williamson, G., The cardiovascular benefits of dark chocolate. Vascul. Pharmacol. 2015, 71, 11–15.
12. Schroeter, H., Heiss, C., Balzer, J., Kleinbongard, P. et al., (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1024–1029.
13. Vlachojannis, J., Erne, P., Zimmermann, B., Chrubasik-Hausmann, S., The impact of cocoa flavanols on cardiovascular health. Phytother. Res. 2016, 30, 1641–1657.
14. Galleano, M., Bernatova, I., Puzserova, A., Balis, P. et al., (-)-Epicatechin reduces blood pressure and improves vasorelaxation in spontaneously hypertensive rats by NO-mediated mechanism. IUBMB Life 2013, 65, 710–715.
15. Jimenez, R., Duarte, J., Perez-Vizcaino, F., Epicatechin: endothelial function and blood pressure. J. Agric. Food Chem. 2012, 60, 8823–8830.
16. Simos, Y. V., Verginadis, I. I., Toliopoulos, I. K., Velalopoulou, A. P. et al., Effects of catechin and epicatechin on superoxide dismutase and glutathione peroxidase activity, in vivo. Redox Report 2012, 17, 181–186.
17. Prince, P. D., Fischerman, L., Toblli, J. E., Fraga, C. G. et al., LPS-induced renal inflammation is prevented by (-)-epicatechin in rats. Redox Biol. 2017, 11, 342–349.
18. Shrime, M. G., Bauer, S. R., McDonald, A. C., Chowdhury, N. H. et al., Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a meta-analysis of short-term studies. J. Nutr. 2011, 141, 1982–1988.
19. Tokede, O. A., Gaziano, J. M., Djousse, L., Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. Eur. J. Clin. Nutr. 2011, 65, 879–886.
20. Hooper, L., Kay, C., Abdelhamid, A., Kroon, P. A. et al., Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am. J. Clin. Nutr. 2012, 95, 740–751.
21. Hartley, L., Flowers, N., Holmes, J., Clarke, A. et al., Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2013, 6, CD009934.
22. Kim, A., Chiu, A., Barone, M. K., Avino, D. et al., Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J. Am. Diet. Assoc. 2011, 111, 1720–1729.
23. Onakpoya, I., Spencer, E., Heneghan, C., Thompson, M., The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 823–836.
24. Hassan, K., Bhalla, V., El Regal, M. E., A-Kader, H. H., Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J. Gastroenterol. 2014, 20, 12082–12101.
25. Abd El-Kader, S. M., El-Den Ashmawy, E. M., Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 2015, 7, 846–858.
26. Van De Wier, B., Koek, G. H., Bast, A., Haenen, G. R., The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit. Rev. Food. Sci. Nutr. 2017, 57, 834–855.
27. Gutierrez-Salmean, G., Ciaraldi, T. P., Nogueira, L., Barboza, J. et al., Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J. Nutr. Biochem. 2014, 25, 91–94.
28. Gutierrez-Salmean, G., Meaney, E., Lanaspa, M. A., Cicerchi, C. et al., A randomized, placebo-controlled, double-blind study on the effects of (-)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: unique in vitro effects. Int. J. Cardiol. 2016, 223, 500–506.
29. Hoek-van den Hil, E. F., van Schothorst, E. M., van der Stelt, I., Swarts, H. J. et al., Direct comparison of metabolic health effects of the flavonoids quercetin, hesperetin, epicatechin, apigenin and anthocyanins in high-fat-diet-fed mice. Genes Nutr 2015, 10, 469.
30. Gao, M., Ma, Y., Liu, D., High-fat diet-induced adiposity, adipose inflammation, hepatic steatosis and hyperinsulinemia in outbred CD-1 mice. PLoS One 2015, 10, e0119784.
31. Huang, T. W., Chang, C. L., Kao, E. S., Lin, J. H., Effect of Hibiscus sabdariffa extract on high fat diet-induced obesity and liver damage in hamsters. Food Nutr. Res. 2015, 59, 29018.
32. Buettner, R., Parhofer, K. G., Woenckhaus, M., Wrede, C. E. et al., Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J. Mol. Endocrinol. 2006, 36, 485–501.
33. Karaçor, K., Çam, M., Orhan, N., Coşgun, E. et al. High fatty diet effects on rat liver. Eur J Gen Med 2014, 11, 99–108.
34. Nair, A. B., Jacob, S., A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016, 7, 27–31.
35. Yang, R. L., Shi, Y. H., Hao, G., Li, W. et al., Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic Index. J Clin Biochem Nutr 2008, 43, 154–158.
36. Zhang, H., Deng, A., Zhang, Z., Yu, Z. et al., The protective effect of epicatechin on experimental ulcerative colitis in mice is mediated by increasing antioxidation and by the inhibition of NF-kappaB pathway. Pharmacol Rep 2016, 68, 514–520.
37. Rustin, P., Munnich, A., Rotig, A., Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Europ. J. Hum. Genet. 2002, 10, 289–291.
38. Tanabe, K., Tamura, Y., Lanaspa, M. A., Miyazaki, M. et al., Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. Am. J. Physiol. Renal. Physiol. 2012, 303, F1264–F1274.
39. Siasos, G., Tousoulis, D., Oikonomou, E., Zaromitidou, M. et al., Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr. Pharm. Des. 2011, 17, 4132–4146.
40. Dower, J. I., Geleijnse, J. M., Gijsbers, L., Schalkwijk, C. et al., Supplementation of the pure flavonoids epicatechin and quercetin affects some biomarkers of endothelial dysfunction and inflammation in (pre)hypertensive adults: a randomized double-blind, placebo-controlled, crossover trial. J. Nutr. 2015, 145, 1459–1463.
41. Loke, W. M., Proudfoot, J. M., Hodgson, J. M., McKinley, A. J. et al., Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 749–757.
42. Shay, J., Elbaz, H. A., Lee, I., Zielske, S. P. et al., Molecular mechanisms and therapeutic effects of (-)-epicatechin and other polyphenols in cancer, inflammation, diabetes, and neurodegeneration. Oxid Med Cell Longev 2015, 2015, 181260.
43. Bettaieb, A., Cremonini, E., Kang, H., Kang, J. et al., Anti-inflammatory actions of (-)-epicatechin in the adipose tissue of obese mice. Int. J. Biochem. Cell Biol. 2016, 81, 383–392.
44. Morrison, M., van der Heijden, R., Heeringa, P., Kaijzel, E. et al., Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NFkappaB in vivo. Atherosclerosis 2014, 233, 149–156.
45. Sullivan, S., Implications of diet on nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 2010, 26, 160–164.
46. Park, H. J., Lee, J. Y., Chung, M. Y., Park, Y. K. et al., Green tea extract suppresses NFkappaB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. J. Nutr. 2012, 142, 57–63.
47. Horton, J. D., Goldstein, J. L., Brown, M. S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002, 109, 1125–1131.
48. Espenshade, P. J., SREBPs: sterol-regulated transcription factors. J. Cell Sci. 2006, 119, 973–976.
49. Aragno, M., Tomasinelli, C. E., Vercellinatto, I., Catalano, M. G. et al., SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free. Radic. Biol. Med. 2009, 47, 1067–1074.
50. Schultz, J. R., Tu, H., Luk, A., Repa, J. J. et al., Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14, 2831–2838.
51. Colak, Y., Ozturk, O., Senates, E., Tuncer, I. et al., SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med. Sci. Monit. 2011, 17, HY5–HY9.
52. Chalkiadaki, A., Guarente, L., High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab 2012, 16, 180–188.
53. Ponugoti, B., Kim, D. H., Xiao, Z., Smith, Z. et al., SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 2010, 285, 33959–33970.
54. Gutierrez-Salmean, G., Ortiz-Vilchis, P., Vacaseydel, C. M., Garduno-Siciliano, L. et al., Effects of (-)-epicatechin on a diet-induced rat model of cardiometabolic risk factors. Eur. J. Pharmacol. 2014, 728, 24–30.